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Background: Cutaneous melanoma is a malignancy with an 
increasing incidence worldwide, especially in northern Europe. The 
aim of this thesis is to scrutinize the results achieved by traditional 
surgery and the opportunities offered by translational research for the 
more advanced stages of the disease.  
 
Paper I analysed outcomes of sentinel node biopsy (SNB) performed 
on 769 consecutive patients with cutaneous melanoma. Breslow 
thickness was the only predictive factor for a positive SN. The 5-year 
melanoma specific survival (MSS) was 81% and in multivariate 
analysis the negative prognostic factors for survival were SN-status, 
followed by Breslow thickness and ulceration. 
 
Paper II reported on 290 consecutive patients who underwent 380 
isolated limb perfusion (ILP), of which 90 were re-ILPs. The results 
between the 1st, the 2nd and the 3-5th were compared. Patients with 
a complete response at the first treatment were likely to have the 
same response at re-ILP without any increase in the risk for local 
toxicity or complications. 
 
Paper III BRAF mutational status as a predictive factor for response 
was studied in 98 patients who underwent ILP. In this consecutive 
series, 32 patients had a BRAF V600E/K mutation and 66 patients 
were BRAF wild type, and no significant correlation for response or 
survival was found. 
 
Paper IV was a translational study based on patient-derived xenograft 
models including 21 cutaneous melanoma biopsies transplanted into 
either NOG or IL-2 transgenic NOG (hIL2-NOG) mice. It was shown 
  
that the models reliably could be used to predict the effect of tumour-
infiltrating lymphocytes against the tumours. 
 
Conclusions: The surgical approach and therapies for patients with 
cutaneous melanoma are becoming more targeted and personalized. 
A specialised multidisciplinary approach can improve the 
understanding of the disease, support the decision-making process 
towards the most advantageous treatment options for each individual 
patient at a specific time.   
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SAMMANFATTNING PÅ SVENSKA 
 
Bakgrund  
Malignt melanom är en hudcancer med ökande förekomst över hela 
världen, särskilt i norra Europa. Syftet med denna avhandling var att 
studera kirurgiska metoder och kombinationen mellan experimentell 
kirurgi och translationell forskning för att behandla de mer avancerade 
stadierna av sjukdom.  
 
Metod 
Kliniska utfall analyserades retrospektivt för patienter som genomgick 
portvaktskörtelbiopsi (sentinel node biopsi, SNB) och isolerad 
hyperterm perfusion (isolated limb perfusion, ILP) på Sahlgrenska 
Universitetssjukhuset, med särskild inriktning på upprepade 
behandlingar (re-ILP) och resultat som relaterats till tumörens 
mutationsstatus. Tumörprover användes dessutom för att skapa en 
biobank och producera avancerade musmodeller med patientens 
egna tumörer, så kallade patient-derived xenografts (PDX). 
 
Resultat 
Studie I inkluderade 769 konsekutiva patienter som genomgått SNB. 
Tumörtjocklek enligt Breslow var den enda prediktiva faktorn för 
positiv SN. Melanomspecifik överlevnad vid 5 år var 81% och i 
multivariatanalys var de viktigaste negativa prognostiska faktorerna 
SN status, följt av Breslow-tjocklek och förekomst av ulceration i 
primärtumören.  
 
Studie II rapporterade 290 konsekutiva patienter som genomgått 
totalt 380 stycken ILP, varav 90 var upprepade behandlingar upp till 
fem gånger på samma patient. Behandlingsresultatet var likvärdigt vid 
upprepad behandling, och de patienter som hade komplett respons 
vid första behandlingen, hade stor sannolikhet för att uppnå detta 
även vid upprepad behandling. Det fanns ingen ökad risk för lokal 
toxicitet eller komplikationer vid upprepad behandling. 
 
Studie III studerade 98 patienter som genomgått ILP och BRAF-
mutationsstatus analyserades som en prediktiv faktor för respons. 
Totalt hade 32 patienter en BRAF V600E/K-mutation och 66 patienter 
var BRAF wild type. Någon signifikant korrelation mellan BRAF-status 
och respons eller överlevnad kunde dock inte visas.  
  
 
Studie IV var en translationell studie baserad på 21 tumörer som 
transplanterats till möss som saknar immunförsvar (NOG) eller 
samma typ av möss som är genetiskt modifierade för att producera 
mänskligt interleukin-2 (hIL2-NOG). Studien har visat att denna 
modell kan användas för att förutsäga immunförsvarets aktivitet mot 
patientens tumör, och att detta därför i framtiden skulle kunna ge en 
vägledning för om patienten kommer att svara på immunterapi eller 
inte. 
 
Slutsats 
Behandlingen av malignt melanom blir allt mer precis och kliniska 
studier gör att vi bättre kan rekommendera patienterna lämplig 
behandling. Möjligheten till att använda avancerade musmodeller av 
patienternas egna tumörer kan även underlätta skräddarsydd 
behandling i en nära framtid.  
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1. INTRODUCTION 
1.1. Melanocyte biology 
Melanocytes have a common origin deriving from neural crest cells, 
they migrate during the embryogenic process as melanoblasts and 
they reach their final destination in the body (skin, conjunctiva, uvea, 
inner ear, brain, heart) where they achieve their mature state [1]. All 
melanocytes have similar biology and basic function with production 
of melanin through a chemical process completed by tyrosinase 
enzymes in the melanosomes. Either eumelanin or pheomelanin is 
produced, depending on the presence or absence of cysteine and 
glutathione in the process [2]. 
 
The mechanism of cellular melanin production and the following 
transfer to the surrounding keratinocytes have an UV radiation 
protective purpose within the skin and conjunctiva [3, 4]. However, the 
role of melanocytes is still far from being understood in other parts of 
the body; other functions that have been proposed, include the 
involvement in hearing and equilibrium functions at the level of the 
inner ear [5-7], a neuroendocrine and anti-oxidative function in the 
brain [8] and mechanic and electrical conductive functions in the heart 
[9, 10]. 
 
1.2. Epidemiology 
Melanomas derive from the cancerogenic proliferation of 
melanocytes, but different types of melanoma are caused by different 
genetic mutations with different incidence, localization and clinical 
characteristics. Cutaneous melanoma is the most frequent 
encountered form, with an incidence of 288,000 new cases per year 
(3.8 per 100,000) as reported by the GLOBOCAN registry in 2018 
[11]. Sweden has the 4th highest incidence in Europe, with 40 per 
100.000 affected men and 43 per 100,000 women, progressively 
increasing year by year [12]. Australia has the highest incidence in 
the world with a reported incidence of 58 per 100,000 for the whole 
country and a peak of 67 per 100,000 in Queensland [13]. The 
incidence is similar worldwide between men and women, even if the 
localization is different. Women more often present with melanomas 
on the lower extremities, while it is more common with trunk 
melanomas in men [14]. 
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1.3. Subtypes  
In 1969 skin melanoma was classified by Clark from a pathologic point 
of view [15]. The superficial spreading melanoma (SSM) is typically 
characterized by two different growth phases, first the radial phase 
and then the vertical phase. Nodular melanoma (NM) usually shows 
an immediate tendency to a vertical growth with a more aggressive 
metastatic behaviour. The lentigo maligna (LM), frequently associated 
with extensive sun exposure and more often affecting elderly patients, 
is characterized by a slow proliferation and infrequent spreading 
behaviour. Acral melanoma (AM) typically has a palmar or plantar 
localization [15]. 
 
1.4. Prognostic factors 
The most important prognostic factors are Breslow thickness, 
ulceration and sentinel node (SN) status [16]. The thickness of the 
tumour lesion according to Breslow, reported in millimetres, is the 
most important parameter in terms of survival. Following Breslow 
criteria, this value is established by measuring the distance between 
the highest point of the granular layer and the deepest level of 
infiltration of the tumour. This kind of measurement is reliable only 
when sections are cut perpendicular to the epidermal layer [17]. 
Ulceration of the primary tumour was reported as an important 
prognostic factor by Allen and Spitz in 1953. They describe this 
condition as the interruption of continuity in a portion of the 
epidermidis layer [18]. 
 
Previously Clark´s level of invasion together with mitotic rate, were 
included in the staging system, however, both these parameters were 
removed in the latest update, but it is still recommended that these 
parameters are reported in the pathology report. Clark´s levels of 
tumour invasion are: level I is confined to the epidermidis (in situ), 
level II is the invasion of the papillary dermis, level III is the 
involvement of the junction between papillary and reticular layer, level 
IV is the invasion of the reticular layer and level V is the presence of 
tumour in the subcutaneous fat [15]. The number of mitosis is reported 
as significant if in excess of 1 per mm2 and is considered a direct sign 
of proliferation activity [19, 20]. 
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1.5. Genetic classification 
From a genetic perspective, cutaneous melanoma is divided based 
on mutational status and is grouped into four categories (Figure 1).  
1. BRAF mutant (v-raf murine sarcoma viral oncogene homolog b) 
2. RAS mutant (neuroblastoma RAS viral v-ras oncogene 
homolog) 
3. NF1 mutant (neurofibromin 1) 
4. Triple wild-type  
 
Figure 1. Landscape of driver mutations in melanoma: Total number of mutations, age 
at melanoma diagnosis, and mutation subtype (BRAF, RAS, NF1, and Triple-wild type) 
are indicated for each sample (top). Color-coded matrix of individual mutations 
(specific BRAF and NRAS mutations indicated) (middle), type of melanoma specimen 
(primary or metastasis), and mutation spectra for all samples (bottom) are indicated. 
For the two samples with both a matched primary and metastatic sample, only the 
mutation information from the metastasis was included. Figure adopted from: Genomic 
Classification of Cutaneous Melanoma. Cancer Genome Atlas Network. Cell. 2015 Jun 
18;161(7):1681-96. 
These different mutations involve the mitogen-activated protein-
kinase (MAPK) pathway with BRAF and NRAS being oncogenes and 
NF1 being a tumour suppressor gene. A mutation in an oncogene 
produces an uncontrolled signal of proliferation, while a mutation in a 
tumour suppressor compromises their function as inhibitors of cell 
proliferation. A NRAS or a BRAF mutation produces a continued 
Figure 1. Landscape of Driver Mutations in Melanoma
(A) Total number of mutations, age at melanoma accession, and mutation subtype (BRAF, RAS [N/H/K],NF1, and Triple-WT) are indicated for each sample (top).
(Not shown are one hyper-mutated and one co-occurring NRAS BRAF hot-spot mutant). Color-coded matrix of individual mutations (specific BRAF and NRAS
mutations indicated) (middle), type of melanoma specimen (primary or metastasis), and mutation spectra for all samples (bottom) are indicated. For the two
samples with both a matched primary and metastatic sample, only the mutation information from the metastasis was included.
(B) BRAF mutations that co-occur with RAS family member and NF1 mutations are illustrated across the BRAF protein.
(C) Fraction of BRAF V600/K601E and non-V600/K601E co-occurring with the RAS (N/H/K), NF1, NF1/RAS (N/H/K) combined cohort and no NF1/RAS (N/H/K)
mutations.
(D) NF1 mutations found in melanoma whole-exome sequencing data across the NF1 protein.
(E) Fraction of NF1 missense and truncating mutations co-occurring with RAS hot-spot or non-BRAF/RAS hot-spot mutations. (Mut, mutation).
See also Figure S1.
Cell 161, 1681–1696, June 18, 2015 ª2015 Elsevier Inc. 1683
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activation of the mitogen-activated protein kinase (MEK) and the 
extracellular signal regulated kinase (ERK) (Figure 2). 
 
BRAF mutations occurs early and are missense mutations (point 
mutations in which a single nucleotide change, results in a codon that 
codes for a different amino acid). The frequency of BRAF mutations 
is around 50% in cutaneous melanoma and around 10 % in mucosal 
melanoma [21]. The most frequent mutations result in the substitution 
of a valine at codon 600, with a glutamate (V600E), lysine (V600K) or 
arginine (V600R). NRAS mutations are found in approximately 25% 
of the patients and NRAS Q61R or Q61K are the most frequent amino 
acid changes resulting from these mutations [22]. 
 
NF1 inactivating mutations are present in approximately 14% of all 
melanoma and this makes the NF-1 protein unable to inhibit the 
GTPase that activates NRAS [22]. The fourth most common setting 
of mutations is the triple negative, where driver mutations in BRAF, 
NRAS or NF1 are lacking. This pattern is instead usually associated 
with the genetic modifications of the receptor tyrosine kinase (KIT) or 
the G protein subunit alpha Q (GNAQ) coding regions. 
 
 
 
Figure 2. The MAPK pathway is a critical driver pathway in melanoma. Here are 
showed the most common mutations associated BRAF, NRAS, and NF-1. Multiple 
target therapies are now available targeting both BRAF and MEK. Figure adopted from: 
The Biology and Therapeutic Approach to BRAF-Mutant Cutaneous Melanoma. Wood 
K., Luke J. The American Journal of Haematology /Oncology. AJHO. 2017;13(1):4-10 
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1.6. Staging 
Melanoma is staged according to the American Joint Committee on 
Cancer (AJCC) staging manual, currently the 8th edition. This system 
includes characteristics of primary tumour (T), status of lymph nodes 
and non-nodal locoregional sites (N), as well as any distant 
metastasis (M) status (Table 1). 
 
Clinical staging Pathologic staging 
Stage 0 Tis N0 M0 Stage 0 Tis N0 M0 
Stage IA 
Stage IB 
T1a 
T1b 
T2a 
N0 
-- 
-- 
M0 
-- 
-- 
Stage IA 
Stage IB 
T1a 
T1b 
T2a 
N0 
-- 
-- 
M0 
-- 
-- 
Stage IIA 
 
Stage IIB 
 
Stage IIC 
T2b 
T3a 
T3b 
T4a 
T4b 
N0 
-- 
-- 
-- 
-- 
M0 
-- 
-- 
-- 
-- 
Stage IIA 
 
Stage IIB 
 
Stage IIC 
T2b 
T3a 
T3b 
T4a 
T4b 
N0 
-- 
-- 
-- 
M0 
-- 
-- 
-- 
Stage III Any T 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
³N1 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
M0 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
Stage IIIA 
 
Stage IIIB 
 
 
 
Stage IIIC 
 
 
 
 
Stage IIID 
T1-2a 
T1-2a 
T0 
T1-2a 
T1-2a 
T2b-3a 
T0 
T0 
T1a-3a 
T3b-4a 
T4b 
T4b 
N1a 
N2a 
N1b-c 
N1b-c 
N2b 
N1a-2b 
N2b-c 
N3b-c 
N2c-3c 
Any N 
N1a-2c 
N3a-c 
M0 
-- 
-- 
-- 
-- 
-- 
M0 
-- 
-- 
-- 
-- 
M0 
Stage IV Any T Any N M1 IV Any T Any N M1 
Table 1. AJCC 8th edition on Melanoma clinical and pathological classification.  
1.6.1. Primary tumour status (T) 
The primary tumour status contains the two most important 
characteristics, Breslow thickness and ulceration. Melanomas with a 
thickness between 1.0 and 2.0 mm are classified as T2; T3 identifies 
lesions between 2.0 and 4.0 mm and T4 are melanomas thicker than 
4.00 mm. Each class is further being divided into “a” or “b” depending 
on the absence or presence of ulceration. The only exception is T1 in 
which T1a is a melanoma less than 0.8 mm without ulceration and 
T1b that includes both an ulcerated lesion less than 0.8 mm or a lesion 
between 0.8-1.0 mm independently of ulceration. 
 
When a primary melanoma has disappeared due to regression or 
when data related to thickness and ulceration is missing this is defined 
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as. In the specific case when the primary lesion was never identified, 
tumour status is defined as a T0. 
 
1.6.2. Lymph node and non-nodal locoregional sites status (N) 
In this category both the status of the regional lymph nodes as well as 
the status of non-nodal locoregional sites (satellites or in-transit 
metastases) are included. The regional draining basins are divided 
into three main N categories based on the number of lymph nodes 
with metastases, N1 when one positive node, N2 when two or three 
positive nodes are present and N3 when more than three lymph 
nodes are present. 
 
Each category is further divided into “a”, “b” and “c”, where “a” is 
defined as “clinically occult” and includes positive sentinel nodes and 
“b” is defined as “clinically detected” nodes and includes nodes 
detected by clinical, radiological or ultrasound examination. The “c” 
category is due to the presence of microsatellite, satellite, or in-transit 
metastases. These are all signs of intra-lymphatic or angiotrophic 
invasion that defines a more severe metastatic disease, even if in the 
presence of a smaller number of involved nodes. Microsatellites are 
small tumour deposits in close proximity of the primary tumour, 
satellites are defined as tumours within 2 cm from the primary tumour 
and in-transit metastasis defined as tumours located beyond 2 cm of 
the primary site and before the first regional draining basin. 
 
When there are no signs of metastatic disease in regional lymph 
nodes this is classified as N0. When the lymph node status is 
unknown this is classified as Nx. 
 
1.6.3. Distant metastasis status (M) 
The M category classifies patients based on the absence (M0) or 
presence (M1) of distant metastatic disease. The M1 class is further 
divided into four levels, “a” for cutaneous and subcutaneous 
metastases or metastases in distant lymph nodes, “b” for lung 
metastasis, “c” for all other visceral sites and “d” for brain metastasis. 
The level of serum lactate dehydrogenase (LDH) is reported as a third 
classifier and is reported as (0) when normal and (1) when increased. 
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1.6.4. Stages 
According to the TNM status, patients are then categorized into four 
different stages (Table 1). Clinical staging is derived by the merge of 
data from the pathologist analysis related to the primary melanoma 
and the evaluation of clinical and radiologic exams regarding regional 
and distant metastases. Pathologic staging includes the information 
retrieved from a SNB or completion lymph node dissection (CLND). 
 
The four stages present a significant difference in survival (Figure 3), 
where the 15-year overall survival is approximately 80% for patients 
in stage I compared to approximately 30% for stage III and 5% for 
stage IV disease. 
 
 
There is also a substantial difference in melanoma specific survival 
(MSS) rates within the Stage III, with the 10-year survival spanning 
between 90% and 20% (Figure 4). 
 
Figure 4. Figure adapted from: Melanoma staging: Evidence-based changes in 
the American Joint Committee on Cancer 7t h edition cancer staging manual. 
Figure 3. Figure adopted with permission from the website Melanoma Molecular Maps 
Projects (http://www.mmmp.org/MMMP/import.mmmp?page=sc_adv.mmmp). 
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Figure 4. Survival between different stages of melanoma I-IV. Figure adopted from 
Melanoma staging: Melanoma staging: Evidence-based changes in the American Joint 
Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 
Nov;67(6):472-492. 
1.7. Surgical treatments 
The removal of a primary pigmented skin lesion, the diagnostic 
excision, has both curative and prognostic value. If the diagnosis is 
melanoma, several factors influence both prognosis and the 
therapeutic strategy. In case of a melanoma in situ, no other surgery 
is needed if the excision was made with at least 5 mm margin. If the 
diagnosis is an invasive melanoma, a wide local excision is 
recommended. 
 
1.7.1. Wide local excision 
The wide local excision related to (WLE) is the surgical excision of the 
previous scar from the diagnostic excision with a margin on the sides 
and extending the excision down to the next anatomical layer, usually 
the muscular fascia, with the aim to remove any potential satellite 
lesions or micro-metastasis spreading from the primary melanoma. In 
Sweden, the recommended margin of resection from the primary 
  9 
tumour scar is 1 cm in case of Breslow thickness ≤ 1.0 mm or 2 cm if 
thicker than 1.0 mm [16]. 
 
The complications after a WLE includes tissue defects, increased 
hospital stay, prolonged rehabilitation, risk of chronic pain and need 
for reconstructive surgery. The current recommended margins have 
been defined by international randomized trials slowly shrinking the 
margins from 5 cm to 1-2 cm. Currently there is a new randomized 
trial evaluating if 1 cm margin is sufficient also for thicker melanomas, 
the MelMart trial [23]. 
 
1.7.2. Sentinel node biopsy and completion lymph node dissection 
The sentinel node (SN) is defined as the first node of a lymphatic 
basin receiving the lymphatic drainage from a specific anatomic area 
[24]. Sentinel node biopsy (SNB) was first introduced for melanoma 
by Morton et al. in 1992. The technique is based on lymphatic tracing 
using a marker which is injected intra-dermally in close proximity to 
the tumour or the previous scar that is then drained through the 
lymphatics and is trapped in the first lymph node for this area, the SN. 
Several markers have been used: blue dye, isotope marked solutions, 
magnetic compounds and others. The SN is removed surgically and 
then analysed by the pathologist deciding if there are tumour deposits 
present. The SN is the most important prognostic factor for patients 
with melanoma, but the therapeutic effect can be questioned [25].  
 
The MSLT-1 trial studied the SNB technique and randomized patients 
into either WLE alone, with delayed LND in case of growth of nodal 
recurrence or WLE and SNB, with immediate completion lymph-node 
dissection (CLND) for patients with a positive SN. No difference in 
survival could be shown, but in a highly discussed sub-group analysis 
(patients with intermediate thickness between 1.2mm and 3.5mm) 
comparing the SN-positive patients with patients showing late 
recurrences in the observation arm, the study reported that there was 
a survival benefit by performing SNB and immediate CLND [26]. 
 
To further explore this finding, the MSLT-2 trial randomized patients 
with positive SN to either CLND or observation of the nodal basin with 
ultrasound. The final results showed no difference in melanoma-
specific survival (MSS), even in the presence of a higher rate of nodal 
recurrences in the observation group [25]. Another study, the German 
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DeCOG-trial, with a similar trial design randomizing patients with 
positive SN to CLND or observation with ultrasound showed no 
difference in MSS [27]. 
 
1.8. Regional therapies 
1.8.1. Isolated limb perfusion  
Isolated limb perfusion (ILP) was initially described by Oscar Creech 
et al. in 1958 [28]. The technique is performed by open surgical 
access to the central venous and arterial blood flow of the limb, which 
is proximally isolated by a tourniquet and then connected to an 
extracorporeal perfusion circuit. A high concentration of a 
chemotherapeutic drug is thereafter circulated through the limb, 
limiting the systemic side effects of the drug, as local or systemic 
toxicity. 
 
The first leakage monitoring system was introduced by Stehlin et al. 
in the early 1960s. The technique was based on the infusion of a 
radioactive mark into the perfusion circuit, testing its own isolation 
level by a scintillation probe fixed over the heart to detect any track of 
radioactivity in the systemic circulation [29]. 
 
ILP has proven to be effective and safe with a high overall response 
rate (ORR) of 90% and low rates of regional and systemic toxicity 
rates [30]. In patients not responding completely, or having a 
recurrence after a previous ILP, a repeated procedure (re-ILP) is 
possible [31-33]. 
 
1.8.2. Isolated limb infusion 
Isolated limb infusion (ILI) was described by John Thompson et al. in 
1996. The procedure is an alternative to ILP and is based on the 
percutaneous placement of arterial and venous catheters passing 
through the contralateral groin without a surgical isolation of the 
vessels. After a radiological evaluation of the catheters position, a 
proximal tourniquet is placed on the affected limb. Using a high-flow 
three-way stopcock syringe, melphalan is infused manually during 20-
30 minutes [34]. No randomized trials comparing ILI and ILP have 
been performed. A retrospective study including 203 patients, of 
whom 94 underwent ILI and 109 ILP, showed and ORR of 53 % for 
ILI and 80 % for ILP [35].   
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1.8.3. Other regional therapies 
Electrochemotherapy (ECT) is a locoregional technique based on a 
selective permeability produced by short electric pulses that open 
ionic membrane channels otherwise impermeable to the 
chemotherapeutic agent bleomycin [36]. A recent prospective cohort 
study showed how this technique can achieve an ORR of 78%, 
including a 54% CR rate [37].  
 
Talimogene laherparepvec (TVEC) is a local injection therapy for 
unresectable metastatic melanoma lesions (stage IIIB–IVM1a) 
approved in a phase III trial (OPTiM) [38]. The mechanism of action 
is based on the injection of a genetically modified herpes simplex virus 
type 1 (HSV1) that selectively replicate inside tumour cells and 
produce granulocyte–macrophage colony-stimulating factor (GM-
CSF). The selective cellular lysis releases cancer-related antigens 
that is phagocytized by antigen-presenting-cells activated by the GM-
CSF [39, 40]. The OPTiM trial reported an ORR of 32% with a CR of 
15% for the injected lesions, and an ORR of 18% with a CR of 6% for 
the non-injected lesions [41]. 
 
PV-10 is another local injection therapy containing a 10% solution 
consisting of the xanthine dye Rose Bengal in a sterile saline. Rose 
Bengal was initially utilised to diagnose ophthalmologic damages and 
liver cancer; its mechanism of action seems to be due to the xanthine 
dye which generates reactive oxygen species causing a phototoxic 
damage. Rose Bengal results both in a direct effect on injected 
lesions by a phototoxic reaction and an indirect action on untreated 
lesions by increasing the up-take of cancer antigens by dendritic cells 
leading to an activation of T lymphocytes [42]. A recently published 
multicentric single arm phase II trial including 62 unresectable stage 
III and 18 stage IV patients reported an ORR of 51% with a CR of 26% 
[43]. 
 
1.9. Systemic treatments 
The medical management of melanoma has undergone remarkable 
changes during the last ten years. Nowadays there are several 
options including traditional chemotherapy, targeted therapies and 
checkpoint inhibitors. 
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1.9.1. Chemotherapy  
Chemotherapy, most frequently based on dacarbazine (DTIC) and 
temozolomide, is currently used as a second or a third line treatment 
for patients in the metastatic setting who are not responding to 
targeted or immuno-therapies. These drugs are working with the 
classical mechanism based on cytotoxic action against rapidly 
proliferating cells [44].  
 
DTIC was first approved in the 1970s with an ORR of 10-20%, 
however with very few CR [45]. The DFS was approximately 3-6 
months with limited number of patients with durable remission [46]. 
There was no impact on OS for patients treated with DTIC. 
Temozolomide did not show any advantage in response or survival 
compared with DTIC, but are orally available and active also at brain 
metastases [47]. 
 
1.9.2. Targeted therapies 
At the moment the most used targeted therapies are BRAF and MEK 
inhibitors. BRAF inhibitors (e.g. vemurafenib or dabrafenib) are 
therapies able to lock the ATP binding site of the MAP kinase, freezing 
the protein at an inactive state [48]. Vemurafenib showed in a 
randomised phase III trial (the BRIM3 trial) an increased OS from 9.7 
to 13.6 months compared to DTIC [49]. 
 
The MEK inhibitors (e.g. trametinib and cobimetinib) action is 
intended to block the MEK protein in the MAPK pathway. Given 
together with BRAF inhibitors this reduce resistance and the phase III 
trial COMBI-d demonstrated an improved OS with the combination of 
dabrafenib and trametinib versus dabrafenib only in BRAF V600E/K-
mutant metastatic melanoma with a 3-year OS of 44% versus 32% 
[50]. New agents have recently been tested as mono or combination 
therapy with promising results. The COLUMBUS study showed that 
combined therapy with encorafenib and binimetinib has a better 
tolerability when compared to other treatments and also better 
response rates [51, 52].  
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1.9.3. Immunotherapy 
Modern immunotherapy is based on recombinant antibodies against 
checkpoint proteins on the cytotoxic T cells, the natural defenders of 
the adaptive immune system. 
 
Ipilimumab is an antibody against the inhibitory checkpoint CTLA-4 
(cytotoxic T-lymphocyte associated antigen-4). When blocking its 
inhibitory activity, CTLA-4 on the surface of the T cells can no longer 
compete with the stimulatory co-receptor CD28 for binding to the B7 
receptor on the surface of antigen presenting cell [53]. A randomized 
trial assigned patients in a 3:1:1 ratio to receive a cancer vaccine 
based on glycoprotein 100 (gp100) alone, gp100 with ipilimumab or 
ipilimumab alone. The median OS were 6.4 months, 10.0 months and 
10.1 months, respectively, showing a significant increase in survival 
for ipilimumab. The ORR was 11% in the ipilimumab group vs. 1.5% 
in the gp100 group [54]. 
 
Nivolumab and pembrolizumab are examples of two monoclonal 
antibodies against PD-1 (programmed cell death 1), a co-inhibitory 
molecule on T cells which, when in contact with ligands (PD-L1, PD-
L2) present on tumour cells and stroma cell, inactivate the T cells. In 
a randomized trial (KEYNOTE-006) pembrolizumab compared to 
ipilimumab showed a 2-year OS of 55% versus 43% [55]. For 
nivolumab a randomized trial (CheckMate 066) showed an OS rate at 
1 year of 73% in the nivolumab group compared to 42% in the DTIC 
group [56]. 
 
1.10. Mouse models in melanoma 
Three kinds of mouse models are most frequently used in melanoma 
research: syngeneic transplants, genetically engineering mouse 
models (GEMM) and xenograft models.   
 
Syngeneic transplants models are based on the transplantation of 
tumour cells that have first developed in mice, often because of 
carcinogen exposure. A frequently used example of this model is 
C57BL/6 mice (e.g. B16-F10) for study of metastases that was 
developed by Fidler [57].  
 
The first example of genetic engineered mouse model (GEMM) was 
“the oncomouse” in 1987 [58]. It was a GEMM carrying a specific 
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transgenic activated oncogene (v-HRas) under control of a mammary 
specific promoter (MMTV), resulting in tumorigenic proliferation. This 
step was an epochal passage that demonstrated in an unequivocal 
way that the expression of oncogenes in normal cells could induce 
the formation of tumours. A second model supporting this theory was 
the tumour suppressor gene TP53  knockout mice reproducing the 
condition of loss or inactivation of tumour suppressors [59]. 
 
In melanoma GEMMs could be grouped in two categories: one 
created by using transgenes or virus carrying oncogenes like 
BRAF/NRAS, and the other based on knock-out mice to target  
tumour suppressor genes in combination with BRAF activation. Here 
Cre recombinase is used to delete a stop cassette upstream of the 
mutated BRAF allele and simultaneously deleting tumour suppressor 
gene PTEN. Cre is in this model expressed specifically in 
melanocytes [60]. 
 
The discovery of CRISPR/Cas9 makes the cancer modelling in mice 
more rapid and flexible with the possibility to insert point mutations, 
translocations or gene deletions. These efforts led to the creation of 
new non-germline models [61]. 
 
A limitation of GEMMs is that they are not human and that they have 
low-mutational load. This can be overcome by using xenograft 
models, the third type of mouse model where the tumour is from 
human cells. One xenograft model is based on either cell derived 
xenografts (CDX) or patient derived xenografts (PDX) [62]. To 
generate xenografts, immunocompromised mice are needed, since 
the tumour would otherwise be rejected. The first 
immunocompromised model was the athymic Nude mice with an 
immune system not able to recognize the human cells as foreign. 
Then several type of immunocompromised mouse models were 
generated. Nude mice do not have functioning T cells, but working B 
and NK cells. 
 
The “Non obese diabetic/severe combined immunodeficiency” (NOD-
SCID) mice lack functioning B and T cells but have very few NK cells. 
NOG/NSG mice are characterized by a further knockout mutation of 
the IL-2 gamma-chain receptor producing inactive B, T and NK cells. 
In our studies we used NOG mouse (e.g. NOD/Shi-scid IL-2Rγnull) 
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which at the moment has the highest efficiency of engraftment of 
human cells. This model lacks functional B, T and NK cells as well as 
having macrophage and dendritic cell dysfunction [63]. 
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2. AIMS OF THE THESIS 
 
The overall aim of the thesis is to analyse the outcomes of four studies 
representing the ongoing evolution in clinical and experimental 
surgery to improve outcome for patients with cutaneous melanoma.  
 
The specific aims are: 
 
- To investigate predictive factors for positive sentinel node (SN) 
and non-SN, as well as prognostic factors for melanoma-specific 
survival. 
 
- To investigate the outcome after repeated isolated limb 
perfusion in terms of safety and efficacy. 
 
- To evaluate the role of BRAF mutational status as a predictive 
factor for response after ILP. 
 
- To establish a biobank with viable tissue and cells from patients 
with melanoma and generate patient-derived xenografts (PDX) 
to model cancer immunotherapy.  
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3. METHODS 
3.1. Study populations 
Paper I 
Between 2000 and 2013, 769 consecutive patients with cutaneous 
melanoma treated with SNB at Sahlgrenska University Hospital were 
included from a prospectively kept database. Data concerning the SN 
tumour load, evaluating the largest tumour deposit, and defined this 
as low if ≤1mm or high when >1mm. The median follow-up time was 
55 months.  
 
Paper II 
Between 2001 and 2015, 290 consecutive patients treated with 380 
ILPs were included from a prospectively kept database at 
Sahlgrenska University Hospital. Ninety of these were re-ILPs, 68 
patients were perfused two times, 16 patients three times, 4 patients 
four times and 2 patients received the treatment 5 times.  
 
Paper III 
Between 2012 and 2017, 111 consecutive patients with melanoma in-
transit metastases treated with first-time ILP at Sahlgrenska 
University Hospital were included from a prospectively kept database. 
Data for both response and BRAF-mutational status were available 
for 98 patients (88%) and these patients were included into the final 
analysis.  There were 32 patients with a BRAF V600E/K mutation 
(33%) and 66 patients having a BRAF wt (66%), equally distributed 
between males and females.  
 
Paper IV 
From 21 patients between 2013 and 2018 at Sahlgrenska University 
Hospital with metastatic melanoma cryopreserved biopsies were 
stored in a biobank.  These tumours were transplanted into either 
NOG mice or hIL2-NOG mice. Clinical follow-up data (treatment, 
response, tumour markers, radiology and survival) were retrieved 
from medical records. An additional patient was also followed with 
real-time biobanking involving biopsy transplantation and TIL 
generation. 
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3.2. Data retrieval 
Data concerning response and progress was collected from a 
prospectively kept database at the Department of Surgery, 
Sahlgrenska University Hospital. Data concerning survival and cause 
of death was recovered from the Swedish National Cause of Death 
Register (Swedish National Board of Health and Welfare). 
 
3.3. Sentinel node biopsy 
Following a diagnostic excision of the primary melanoma (Stage 1-2) 
patients underwent WLE and SNB. SNB was performed using the 
combination of a lympho-scintigraphy, blue dye injection and the use 
of an intraoperative gamma probe. The day before surgery 80Mbq 
technetium-99-nanocolloid was injected around the primary tumour 
site. After two hours images were acquired to track the main lymphatic 
drainage and to find the first draining lymph node. Patent Blue Violet 
(Patent Blue V 2.5%; Guerbet, Aulnay-sous-Bois, France) was 
injected immediately before the intervention in the operating theatre 
intracutaneously in four points around the scar of the primary lesion. 
The removed lymph nodes were sent for pathological examination 
using haematoxylin and eosin staining. Starting in May 2013, also 
immunohistochemistry using the markers S-100, Melan-A and HMB-
45 were used routinely. Patients with a positive SN were planned for 
a CLND. 
 
3.4. Isolated limb perfusion 
The vascular system of the treated limb was isolated by cannulation 
and clamping of the major artery and vein, which were then connected 
to an oxygenated extracorporeal circuit. The remaining collateral 
vessels were compressed with a proximal inflatable tourniquet 
(Zimmer disposable tourniquet) or an Esmarch bandage.  
 
For first-time ILPs, melphalan (M-ILP) (Alkeran®, GlaxoSmithKline 
Pharmaceuticals, Research Triangle Park, NC) was used. The 
addition of tumour necrosis factor-alpha (TNF-alpha, Beromun®, 
Boehringer Ingelheim, Germany) (TM-ILP) was considered primarily 
for bulky melanomas (tumours with a diameter larger than 30 mm) but 
also for re-ILPs. 
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In M-ILP, the dose of melphalan was calculated according to the limb 
volume using 13mg/L for upper limb and 10 mg/L for lower limb 
perfusions. Before 2012, melphalan was given as three bolus doses, 
with 50% of the total dose administered initially and the remaining 
50% administered in two equivalent doses at 30-minute intervals, with 
a total perfusion time of 90 minutes. In 2012 the administration of 
melphalan was changed to a 20 minutes infusion into the perfusion 
circuit and a total perfusion time of 60 minutes [64]. 
 
In patients receiving TM-ILP, a bolus dose of TNF-alpha was injected 
into the perfusion circuit (3 mg for upper limb and 4 mg for lower limb), 
provided that the limb tissue temperature had reached 38°C. Thirty 
minutes later melphalan was then administered during a 20 minutes 
infusion. The total perfusion time was 90 minutes. All treatments were 
performed under mild hyperthermia (39-40°C). After perfusion, the 
limb was rinsed with at least 1–2 L (upper limb) or 3–4 L (lower limb) 
of Ringer’s solution (Ringer Acetate, Baxter, Sweden). No 
adjustments in perfusion characteristics were made for re-ILPs. 
 
During the procedure, continuous leakage monitoring was performed 
with a precordial scintillation probe (MedicView, Gothenburg, 
Sweden) to detect and measure leakage of technetium-99m labelled 
human serum albumin (Vasculosis, Cis Bio, France) injected into the 
perfusion circuit.  
 
3.5. Response evaluation 
Response was evaluated according to the WHO criteria at 3 months 
from treatment [65]. A complete response (CR) was defined as the 
disappearance of all lesions. Partial response (PR) was categorized 
a reduction of more than 50% of the total tumour burden. Progressive 
disease (PD) was identified by a growth in volume of more than 25% 
of the existing lesions or the appearance of new ones. Stable disease 
(SD) describe the condition in which criteria for CR, PR or PD were 
not fulfilled. 
 
3.6. Evaluation of toxicity and complications 
Local toxicity was monitored and evaluated by a physician up to three 
months after ILP and graded as the worst toxicity during that time 
according to the Wieberdink classification; grade I (no reaction), grade 
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II (erythema or swelling), grade III (major erythema, swelling or 
blistering), grade IV (extensive epidermolysis and/or damage to deep 
tissues, causing final functional disorders; risk or manifest 
compartment syndrome) and grade V (reaction that may necessitate 
amputation) [66].  
 
Complications within 30 days post-operatively were graded according 
to the Clavien-Dindo classification [67]. 
 
3.7. Statistical methods 
Univariate and multivariate logistic regression analysis using the 
Enter method were performed to find predictive factors for SN and 
non-sentinel node (NSN) positivity after surgery and for response and 
toxicity after ILP. False negative rate (FNR) was defined as the ratio 
between false negative cases and the total number of false negative 
and true positives. 
 
Disease-free survival (DFS) was defined as the time between surgery 
and recurrence as detected with either clinical or radiological 
examination. Survival was calculated from surgery or first ILP to 
death, either from melanoma (melanoma-specific survival, MSS) or 
including other causes (overall survival, OS). The Kaplan-Meier 
method was used to perform time-to-event curves, then compared 
with the log rank test. Cox proportional hazard regression analysis 
using the enter method was used for multivariate analysis.  
 
A p-value of <0.05 was considered significant. Missing data were 
excluded from the analysis. IBM SPSS Statistics version 25.0 (IBM 
Corp., Armonk, New York, USA) was used for statistical analysis. 
 
3.8. Laboratory analysis of BRAF mutational status 
BRAF gene mutation analysis uses DNA sequencing to detect 
mutations in the BRAF oncogene. The test is used routinely in 
Sweden for patients with melanoma stage III and IV, and the analysis 
is performed by six different clinical molecular pathology laboratories 
in the different Swedish regions. Data concerning BRAF-mutational 
status was retrieved from the clinical molecular pathology 
departments of the referring hospitals. 
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3.9. Patient-derived xenografts 
Following informed consent (Ethics approvals #288-12 and #44-18), 
patient-derived xenografts (PDX) were created by subcutaneous 
injections of tumour cells from patients with melanoma into NOG mice 
(Figure 5). 
 
 
Figure 5. Patient derived xenograft model standard procedure. Figure adopted from: 
Einarsdottir, B.O., et al., Melanoma patient-derived xenografts accurately model the 
disease and develop fast enough to guide treatment decisions. Oncotarget, 2014. 
5(20): p. 9609-18. 
 
This model had the limitation of not modelling the interaction between 
tumour cells and the immune system, since NOG mice are defect in 
number and function of B, T and dendritic cells, and defect in function 
and reduced numbers of natural killer cells. Another model called 
PDXv2 was developed; in this model both tumour cells and the tumour 
infiltrating lymphocytes (TILS) expanded in cell culture were injected 
into the mice (Figure 6) [68]. For this model to support viability of 
human T cells, a transgenic NOG mouse expressing human IL-2 
(hIL2-NOG). We also transplanted biopsies from patients directly into 
NOG or hIL2-NOG mice. 
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Figure 6. In this schema is shown the isolation process from a tumour sample of both 
cancer cells and TILS, then respectively injected in mice and expanded in lab culture. 
Figure adopted from: Jespersen H et al. Clinical responses to adoptive T-cell transfer 
can be modelled in an autologous immune-humanized mouse model. Nat Commun. 
2017 Sep 27;8(1):707.  
 
For both PDXv2 and biopsy transplantation models, tumour initiation 
was performed by a 1:1 ratio mix of cell suspensions and Matrigel, 
then injected in the subcutaneous tissue of 8-24 weeks-old NOG mice 
or hIL2-NOG mice (from Taconic or own breeding colony). Twice a 
week tumour growth was checked by caliper measurement. The 
tumour volumes were calculated using the formula (length x width2)/2. 
The mouse was sacrificed when a tumour reached more than 10 mm 
in the base, or it was registered a loss of weight higher than 20%. 
 
In PDXv2, tumours growing in NOG mice were serially transplanted 
into hIL2-NOG mice. Twenty million TILs were injected either when 
tumours had grown or five days after tumour implantation. 
 
3.10. Production of TILs 
Tumour biopsies were cut into small pieces, and TILs were produced 
by culturing bioptic samples in 24-well plates in TIL medium (RPMI, 
10% human serum and 6000 U/ml IL-2 from Peprotech). These young 
TIL (yTIL) cultures were either cryopreserved or used in a rapid 
expansion protocol (REP) for in vivo experiments. For REP, yTILs 
were mixed with irradiated feeders from allogenic donors 
(Sahlgrenska Blood Depository) and cultured in REP medium (50% 
RPMI, 40% AIM V, 10 % human serum, 6000 U/ml IL-2 and 30 ng/ml 
anti-CD3 antibody (OKT3 antibody).  
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3.11. Genomics 
DNA and RNA were extracted from tumours and TILs using a kit 
(Qiagen). Exome and RNA-seq was performed in the lab 
(GeneCoreSU) and raw reads were aligned to the human genome. 
TILs were used as normal controls for exome sequencing data.  
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4. RESULTS AND DISCUSSION 
4.1. Paper I 
This study includes the outcome of all SNB performed at Sahlgrenska 
University Hospital between 2000 and 2013. During this period the 
number of procedures per year increased significantly and SNB 
became a routine management for T1b-T4 melanomas. Across the 
study period the rate of positive SN was 14%, which is comparable to 
other reports ranging between 13% and 31% [69, 70]. 
 
The FNR was 20% for the entire period, comparable with previous 
studies ranging between 9% and 21% [71, 72], reducing progressively 
during the years to settle around 17% in the last time period [73-75]. 
This confirms the existence of a learning curve in performing a SNB 
favouring the centralization of specialist surgery within dedicated 
cancer centres [76]. The only independent predictive factor for a 
positive SN found in our series was Breslow thickness. It was not 
possible to identify already known predictive factors such as 
ulceration, age or tumour site as predictive for SN positivity. Other 
known predictive factors with less importance, such as regression, 
lympho-vascular invasion and mitosis of the primary tumour was not 
included in the analysis [19, 26, 73, 77-79]. 
 
A positive non-sentinel node (NSN) was detected in approximately 
20% of the patients with a positive SN that underwent CLND. 
Independent predictive factors for positive NSN were reported and 
extensively analysed by Madu et al. They found that the largest 
diameter in SN metastasis was the most important predictive factor 
[80]. Our study could not confirm this observation, possibly due to the 
low number of patients with positive NSN. 
 
In terms of survival the most important prognostic factors were shown 
to be SN-status, Breslow thickness and ulceration. These findings 
confirm the importance of these parameters as the most important 
prognostic factors for melanoma according to the current AJCC 
classification [16, 81]. The 5-year MSS was 81% and there was no 
difference in MSS related to the tumour load in SN (Figure 7), which 
is different from other previous reports [82-84]. Potentially this could 
be due to the differences in the pathological analysis of the SN, where 
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more information concerning the tumour load could have been 
obtained by e.g. the Rotterdam criteria [84].  
 
 
 
Figure 7. Kaplan Meier survival curves in patients that underwent SNB. 
 
4.2. Paper II 
Clinical response was analysed in 380 ILPs and the outcomes were 
evaluated dividing the population into three groups: patients who 
underwent only one ILP, patients treated twice and patients who 
received three to five ILPs. The ORR registered for the three groups 
was 83%, 80% and 68% with a CR rate of 60%, 41% and 59%. 
 
In this study the response for first-time ILPs was comparable to 
previous results from our own institution [64, 85] and also to previous 
reports from other units [30]. On the other hand, when only analysing 
the re-ILPs, we discovered that our response rates were in the lower 
range with a CR rate of 52%, compared to other major studies on re-
ILP reporting a CR rate between 62% and 76% [31-33]. This result is 
probably due to a selection bias, where other institutions mainly 
perform re-ILPs in patients with recurrences following complete or 
near-complete response after previous ILP [31-33], while in our 
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series, many re-ILPs were 
on patients not responding 
after the first ILP (Figure 8).   
 
In this study 2/3 of the 
patients developed a grade 
I/II toxicity independently of 
the number of ILPs; these 
findings are similar to those 
of other series reporting 
grade I/II reactions between 
66 and 73% [30-33]. Severe 
reactions such as grade IV 
toxicity were 7% in this 
series, which is higher than 
other reports ranging 
between 0% and 5% [30-
33]. A potential explanation could be a more accurate long-term 
follow-up of the patients, where any deficit in limb sensitivity or motor 
function was reported as a persistent grade IV toxicity. In our practice 
re-ILP were performed using previous incisions, making the surgical 
access more challenging, but without an increase in complications, 
when compared to first-time ILPs.  
 
The use of TNF-alpha in re-ILPs have been highly discussed. In the 
group of first-time ILPs, there was a difference in response after M-
ILP and after TM-ILP, with a CR rate of 63% and 33% respectively. 
This finding is probably due to the use of TNF-alpha only for bulky 
tumours, where the tumour load is a negative predictive factor for 
obtaining a full response. In the re-ILPs, TNF-alpha was not used in 
17 patients and in this group both the OR and CR rates were lower, 
however not statistically significant in neither univariate nor 
multivariate analyses. From the current results it was not possible to 
draw any definitive conclusions about the role of TNF-alpha in the re-
ILP. 
 
The overall survival time was 34 months, 41 months and 93 months, 
respectively for patients who underwent only one ILP, patients treated 
twice and patients who received 3-5 ILPs (p=0.02). The OS was 
significantly higher in patients receiving repeated ILPs. This is 
THE SAHLGRENSKA ACADEMY
1st ILP n=68
CR no-CR
29 pts (52%) 27 pts (48%)
2nd  ILP n=56
CR no-CR CR     no-CR 
15 pts (65%)           8 pts (35%)               2 pts (8%)           22 pts (92%)
Response
Figure 8. Patients response to ILP, showing 
the higher number of CR after a second ILPs in 
patients who had a CR already at first ILP.  
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probably explained by a selection bias and not as a consequence of 
the ILP treatment itself. Patients with longer survival are more prone 
to the risk of loco-regional relapse and they consequently have a 
higher risk of being treated with a re-ILP. 
 
4.3. Paper III 
In this study response and BRAF-mutational status were studied in 
98 patients treated with a first-time ILP. The ORR was 69% for BRAF 
V600E/K and 77% for BRAF wt (p=0.36). The CR rate for BRAF 
V600E/K and for BRAF wt patients was 47% and 52%, respectively 
(p=0.67). At univariate analysis, only stage and tumour size were 
significant predictive factors for a CR, but in the multivariate logistic 
regression analysis no independent predictive factor was identified 
(Table 2). Taken together, the BRAF status do not influence the 
response rates after ILP. 
 
Table 2. Univariate and multivariate logistic regression for complete response. 
 
 Univariate analysis Multivariate analysis 
 OR 95% CI p-value OR 95% CI p-value 
Age (year) 1.0 0.9-1.1 0.4 1.0 0.9-1.0 0.6 
Gender 
   Female* vs. Male 
 
0.7 
 
0.3-1.5 
 
0.3 
 
0.6 
 
0.2-1.4 
 
0.2 
Stage 
   N2c* vs. N3 
   N2c* vs. M1 
 
10.4 
13.0 
 
1.2-87.5 
1.5-111.8 
 
0.03 
0.02 
 
1.7 
0.2 
 
0.6-4.6 
0.1-2.5 
 
0.3 
0.2 
Numbers of tumors 
   ≤ 10* vs. > 10 
 
0.5 
 
0.2-1.1 
 
0.1 
 
0.6 
 
0.2-1.6 
 
0.3 
Tumor size 
   ≤ 30 mm* vs. > 30 mm 
 
0.2 
 
0.1-0.8 
 
0.02 
 
0.4 
 
0.8-1.7 
 
0.2 
Chemotherapy    
   M-ILP* vs. TM-ILP 
 
0.2 
 
0.1-2.0 
 
0.2 
 
0.8 
 
0.1-13.8 
 
0.9 
Mutational Status  
   BRAF wild type* vs. BRAF V600E/K 
 
0.8 
 
0.3-1.9 
 
0.7 
 
0.6 
 
0.2-1.6 
 
0.3 
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Our results are concordant with those previously presented by Li et 
al. on 150 patients, where BRAF status was not found to be predictive 
for response after ILI [86]. This is however in contrast to Gallagher et 
al. which reported on 30 patients treated with ILI, where BRAF 
V600E/K was found as a predictive factor for a poorer response [87].  
 
The median survival was 47 months. For the BRAF V600E/K patients 
the median survival was not reached, while it was 44 months for the 
BRAF wt group. The 2-year OS was 51% for the BRAF V600E/K 
group and 49% for the BRAF wt group. In univariate Cox regression 
analysis age, sex, stage and tumour size were identified as prognostic 
factors, however at the multivariate analysis the only independent 
factors were age and stage. There are conflicting results reported for 
the prognostic value of BRAF mutational status for survival. An 
analysis including 197 patients with unresectable stage IIIC and stage 
IV melanoma demonstrated a worse prognosis for patients carrying a 
BRAF V600E/K mutation (5.7 months instead of 8.5 months) [88]. 
This can be compared to a study by Carlino et al. including 192 
patients not treated with BRAF-inhibitors, where BRAF mutational 
status was not identified as a prognostic factor [89].   
 
4.4. Paper IV 
In this study we reported the use of an immune-humanized mouse 
model as a functional biomarker of response to immunotherapy. In 21 
patients it was possible to generate both PDX models and TILs. For 
each patient we created two animal models by injecting biopsies from 
patients with melanoma; one in a wild type NOG mouse (NOG/wt) and 
the other in a mouse expressing human IL2 (hIL2-NOG). We 
observed that TILs in injected biopsies were not able to stop the 
tumour growth in NOG mice, while in hIL2-NOG mice TILs from some 
of the biopsies were able to inhibit cancer growth in some of the 
models. 
 
There is a lack of methods to predict response to PD-1 inhibitors, and 
neither mutational load, PD-L1 expression or new markers such as 
IMPRESS or TIDE are reliable [90, 91]. In this series, the 
corresponding patients that received systemic immunotherapy, had 
similar responses as shown in the PDX models, suggesting that the 
model might be predictive. As an example, a subcutaneous 
metastasis was surgically removed from a patient with a BRAF 
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mutated melanoma. When analysing the sample, it was not possible 
to isolate any TILs. After the surgery the patient was treated with 
BRAF and MEK inhibitors and responded to therapy. A new biopsy 
was taken and it was now possible to isolate a large number of TILs, 
but very few tumour cells. We injected tumour cells and TILs from 
these two samples in NOG/wt and hIL2-NOG mice. The first sample 
of the patient showed tumour growth in both models while the second 
biopsy grew very slow. The patient was switched to anti-PD1 inhibitor 
and more lesions disappeared. Biopsies during treatment grew in 
NOG but not in hIL2-NOG. 
 
After two months the patient progressed with new metastases. One 
superficial metastasis was surgically removed before a re-challenge 
with BRAF/MEK inhibitors. This biopsy grew both in NOG and hIL2-
NOG mice, showing that the last TILs were incapable of killing the 
cancer cells. 
 
Taken together these data suggest that responses in mice can be 
used to support clinical decisions. It is indeed plausible that in the 
future, PDX models will have a chance to guide second and third-line 
therapies, considering the continuous improvements of clinical 
efficacy of immunotherapy in correctly selected patients. The obvious 
limitations of our study and the interpretation are the limited number 
of samples, and that the biobank was retrospective. However, we 
were able to show its value supporting the clinical management of 
patients with metastatic melanoma. 
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5. CONCLUSION 
 
Ø Breslow thickness was the only independent predictive factor for 
a positive sentinel node. The prognostic factors for melanoma-
specific survival were sentinel node status, Breslow thickness 
and ulceration. Sentinel node tumour load were not prognostic 
for survival. We reported a decrease in false negative rate over 
time with results comparable to other international institutions. 
 
Ø Patients having a complete response after the first ILP were 
likely to have the same response at re-ILP without any increase 
in the risk for local toxicity or complications. 
 
Ø BRAF mutational status of patients with melanoma in-transit 
metastases treated with ILP, was not a significant factor for 
response nor survival. 
 
Ø The use of advanced PDX models could potentially be used to 
predict response to immunotherapy in patients with melanoma 
metastases. 
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